logo
  • About
    • The Idea
    • The Concept
    • Strategy
  • Opportunity
    • The Need
    • The Market
    • The Unique Concept
    • The Competition
  • Scientific Foundation
    • Knowledge Platform
    • Modes of Action
    • Results
    • IPR
  • Publications
  • Team
  • News
  • Contact

Excellent results from phase I study shows that the BioC gel is safe and well tolerated.

15 September, 2022
|In News
|By Helene Hartman

The first part of the phase I study has now been unblinded. The result shows that BioC gel is both safe and well tolerated. There were no adverse events reported and no systemic effect detected.

Recent Posts

  • Xinnate raises SEK 31 million in oversubscribed share issue
  • New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD
  • Xinnate announces successful FDA meeting for TCP-25
  • Xinnate receives Orphan Drug Designation from US FDA for TCP-25
  • Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm

Archives

  • July 2025
  • June 2025
  • May 2025
  • January 2025
  • December 2024
  • September 2024
  • May 2024
  • March 2024
  • February 2024
  • March 2023
  • October 2022
  • September 2022
  • July 2022
  • March 2022
  • August 2021
  • October 2020
  • January 2020
  • Prev
  • Next
© 2025 Xinnate. All rights reserved